OLD--Lloyd, J. The Cancer Research Institute (CRI) grieves the passing of its founding scientific and medical director, Lloyd J. Old, M.D., the Father of Modern Tumor Immunology, who died from prostate cancer Monday morning at age 78. Lloyd was a pioneer with a distinguished scientific career, whose passionate belief that the immune system could be harnessed to control and eventually cure cancer inspired generations of tumor immunologists. From his numerous seminal contributions to our understanding of the immune system and its relationship to cancer, through forty years as director of CRI's scientific programs, to his visionary leadership in bringing together CRI and the Ludwig Institute for Cancer Research (LICR) to form the CRI/LICR Cancer Vaccine Collaborative, a jointly directed global clinical trials network established in 2001 to accelerate development of therapeutic cancer vaccines, Dr. Old transformed the fields of immunology and tumor immunology and made possible many of today's advances in immune system-based treatment of cancer. Although his imprint on the Cancer Research Institute and on the future of cancer treatment is strong, and his legacy of vision and leadership lives on through our work and the work of thousands of scientists who have been touched by Dr. Old's scholarship, generosity, and support, we nevertheless will feel deeply the absence of this caring, considerate, and highly intelligent man for whom we have the profoundest respect and admiration. Our condolences go to Dr. Old's sister, Constance, nephews, Christopher and Albert, niece, Letitia, and to his closest colleagues and many friends. Board of Trustees, Scientific Advisory Council, and Staff, â€¨Cancer Research Institute
The Guest Book is expired.
Published in The New York Times on Nov. 30, 2011